Digital.CSIC > Ciencia y Tecnologías Químicas > Instituto de Investigaciones Químicas (IIQ) > (IIQ) Artículos >





Closed Access item Chaperone Activity of Bicyclic Nojirimycin Analogues for Gaucher Mutations in Comparison with N-(n-nonyl)Deoxynojirimycin

Authors:Luan, Zhuo
Higaki, Katsumi
Aguilar Moncayo, Matilde
Ninomiya, Haruaki
Ohno, Kousaku
García Moreno, María Isabel
Ortiz-Mellet, Carmen
García-Fernández, José Manuel
Suzuki, Yoshiyuki
Keywords:Gaucher disease, Glucocerebrosidase, Glucosidase, Imino sugars, Inhibitors, Medicinal chemistry
Issue Date:14-Oct-2009
Citation:ChemBioChem 10(17): 2780-2792 (2009)
Abstract:Gaucher disease (GD), the most prevalent lysosomal storage disorder, is caused by mutations of lysosomal β-glucosidase (acid β-Glu, β-glucocerebrosidase); these mutations result in protein misfolding. Some inhibitors of this enzyme, such as the iminosugar glucomimetic N-(n-nonyl)-1-deoxynojirimycin (NN-DNJ), are known to bind to the active site and stabilize the proper folding for the catalytic form, acting as “chemical chaperones” that facilitate transport and maturation of acid β-Glu. Recently, bicyclic nojirimycin (NJ) analogues with structure of sp2 iminosugars were found to behave as very selective, competitive inhibitors of the lysosomal β-Glu. We have now evaluated the glycosidase inhibitory profile of a series of six compounds within this family, namely 5-N,6-O-(N′-octyliminomethylidene-NJ (NOI-NJ), the 6-thio and 6-amino-6-deoxy derivatives (6S-NOI-NJ and 6N-NOI-NJ) and the corresponding galactonojirimycin (GNJ) counterparts (NOI-GNJ, 6S-NOI-GNJ and 6N-NOI-GNJ), against commercial as well as lysosomal glycosidases. The chaperone effects of four selected candidates (NOI-NJ, 6S-NOI-NJ, 6N-NOI-NJ, and 6S-NOI-GNJ) were further evaluated in GD fibroblasts with various acid β-Glu mutations. The compounds showed enzyme enhancement on human fibroblasts with N188S, G202R, F213I or N370S mutations. The chaperone effects of the sp2 iminosugar were generally stronger than those observed for NN-DNJ; this suggests that these compounds are promising candidates for clinical treatment of GD patients with a broad range of β-Glu mutations, especially for neuronopathic forms of Gaucher disease.
Description:13 páginas, 2 figuras, 3 tablas, 4 esquemas
Publisher version (URL):http://dx.doi.org/10.1002/cbic.200900442
E-ISSNmetadata.dc.identifier.doi = DOI:1439-7633
Appears in Collections:(IIQ) Artículos

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.